[go: up one dir, main page]

CN109153676A - Nbi-98854的晶型及其制备方法和用途 - Google Patents

Nbi-98854的晶型及其制备方法和用途 Download PDF

Info

Publication number
CN109153676A
CN109153676A CN201780029517.5A CN201780029517A CN109153676A CN 109153676 A CN109153676 A CN 109153676A CN 201780029517 A CN201780029517 A CN 201780029517A CN 109153676 A CN109153676 A CN 109153676A
Authority
CN
China
Prior art keywords
crystal form
nbi
solid
preparation
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780029517.5A
Other languages
English (en)
Other versions
CN109153676B (zh
Inventor
陈敏华
张炎锋
邹坡
刘凯
王金秋
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmaceutical Suzhou Co Ltd
Original Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmaceutical Suzhou Co Ltd filed Critical Crystal Pharmaceutical Suzhou Co Ltd
Publication of CN109153676A publication Critical patent/CN109153676A/zh
Application granted granted Critical
Publication of CN109153676B publication Critical patent/CN109153676B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种NBI‑98854(结构如式I所示)的晶型及其制备方法和用途。所述的NBI‑98854晶型分别命名为晶型CS1、晶型CS2，可用于制备治疗迟发性运动障碍的药物。所述的NBI‑98854晶型的溶解度、引湿性符合药用要求，稳定性好，能稳定储存，避免药物在开发过程中发生转晶，从而避免药物溶解度、溶出率、生物利用度以及药效的改变。为含NBI‑98854的药物制剂的制备提供了新的更好的选择，对于药物开发具有非常重要的意义。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201780029517.5A 2016-06-29 2017-06-29 Nbi-98854的晶型及其制备方法和用途 Expired - Fee Related CN109153676B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016104889767 2016-06-29
CN201610488976 2016-06-29
PCT/CN2017/090926 WO2018001335A1 (zh) 2016-06-29 2017-06-29 Nbi-98854的晶型及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN109153676A true CN109153676A (zh) 2019-01-04
CN109153676B CN109153676B (zh) 2021-08-10

Family

ID=60785885

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780029517.5A Expired - Fee Related CN109153676B (zh) 2016-06-29 2017-06-29 Nbi-98854的晶型及其制备方法和用途

Country Status (5)

Country Link
US (1) US10442800B2 (zh)
EP (1) EP3473623B1 (zh)
CN (1) CN109153676B (zh)
ES (1) ES2811048T3 (zh)
WO (1) WO2018001335A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
WO2018067945A1 (en) * 2016-10-06 2018-04-12 Assia Chemical Industries Ltd. Solid state forms of valbenazine
WO2018130345A1 (en) * 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113368110A (zh) 2014-02-07 2021-09-10 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
RU2771164C2 (ru) * 2017-04-01 2022-04-27 Адептио Фармасьютикалз Лимитед (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553487A (zh) * 2006-11-08 2009-10-07 纽罗克里生物科学有限公司 取代的3-异丁基-9,10-二甲氧基-1,3,4,6,7,11b-六氢-2H-吡啶并[2,1-a]异喹啉-2-醇化合物和与其相关的方法
WO2015120110A2 (en) * 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
WO2018067945A1 (en) * 2016-10-06 2018-04-12 Assia Chemical Industries Ltd. Solid state forms of valbenazine
WO2018130345A1 (en) * 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANON: ""A crystalline form of L-valine (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester"", 《IP.COM JOURNAL》 *
ANON: ""Novel preparation of crystalline forms L1 and L2 of L-valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester"", 《IP.COM JOURNAL》 *

Also Published As

Publication number Publication date
EP3473623A4 (en) 2019-06-12
WO2018001335A1 (zh) 2018-01-04
ES2811048T3 (es) 2021-03-10
EP3473623A1 (en) 2019-04-24
CN109153676B (zh) 2021-08-10
US20190218209A1 (en) 2019-07-18
EP3473623B1 (en) 2020-07-15
US10442800B2 (en) 2019-10-15

Similar Documents

Publication Publication Date Title
CN105111215B (zh) 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
CN109153656A (zh) 他发米帝司葡甲胺盐的晶型e及其制备方法和用途
CN108884111A (zh) 克立硼罗游离形式的晶型及其制备方法和用途
CN109219597A (zh) 奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
WO2016165650A1 (zh) 奥拉帕尼与尿素的共晶及其制备方法
CN105732575A (zh) 一种治疗前列腺癌的新型抗雄激素类药物的新晶型及其制备方法
CN109548403A (zh) Galunisertib的晶型及其制备方法和用途
CN110128356A (zh) 一种吉非替尼与3-羟基苯甲酸共晶体
WO2022170864A1 (zh) Belumosudil甲磺酸盐的晶型及其制备方法和用途
CN106397298B (zh) 含吲哚布芬的药物组合物和用途
CN110156700A (zh) 吉非替尼与水杨酸共晶体
CN104649969B (zh) 一种替尼类药物的盐及其制备方法
CN109153676A (zh) Nbi-98854的晶型及其制备方法和用途
CN103044364B (zh) 一种卡巴他赛无定形晶及其制备方法
CN103664929B (zh) 达沙替尼多晶型药物及制备方法
WO2015113370A1 (zh) 一种甜菊糖a苷晶体及其制备方法和用途
CN105315260A (zh) 一种托布司他一水合物晶型及其制备方法
CN108329308A (zh) 一种二氢嘧啶类化合物的固体形式及其制备方法
CN114644642B (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
WO2020186962A1 (zh) 一种草乌甲素e晶型及其制备方法与应用
CN105037391B (zh) 一种头孢孟多酯钠化合物及其制剂
WO2015113369A1 (zh) 一种甜菊糖a苷晶体及其制备方法和用途
CN104961681A (zh) 卡博替尼的粘酸盐及其晶型
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
CN105949183B (zh) 阿齐沙坦酯的晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210810